Michael Ciarametaro, MBA, vice president of research at the National Pharmaceutical Council (NPC), explains the ways that the gene therapy market is working to address concerns regarding contractual riders for value-based contracts for expensive therapies.
Michael Ciarametaro, MBA, vice president of research at the National Pharmaceutical Council (NPC), explains the ways that the gene therapy market is working to address concerns regarding contractual riders for value-based contracts for expensive therapies.
Transcript
Are contractual riders for value-based contracts for expensive treatments like gene therapies, which allow the payer who took on the cost of the therapy to keep receiving payments even after a patient moves to another insurer, actually being used in the real world?
It's a good question. These types of arrangements are in the early stages. If you recall, the reforms to Medicaid best price don't go into effect until July. So, we're not seeing a ton of movement at the moment. But the market is working toward addressing these concerns in 3 ways.
First, the large payers have indicated that they can track outcomes over time if there's agreement between the old and the new payer.
Second, there are third parties out there now that offer to completely outsource the management of these value-based contracts. They will set up the contract, and they will track the outcomes over time.
Third, there are other alternative approaches in terms of how you manage gene therapies. There are carve-outs now available, where basically a purchaser pays a flat per-member per-month fee to a third party and they have financial responsibility for the drug. In that sense, you no longer have the problem of the patient moving because it always constantly resides with that third party.
What's at Stake as Oral Arguments Are Presented in the Braidwood Case? Q&A With Richard Hughes IV
April 21st 2025Richard Hughes IV, JD, MPH, spoke about the upcoming oral arguments to be presented to the Supreme Court regarding the Braidwood case, which would determine how preventive services are guaranteed insurance coverage.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Orca-T showed lower rates of graft-vs-host disease or infection compared with allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome (MDS) or acute leukemias in the Precision-T trial, Caspian Oliai, MD, MS, UCLA Bone Marrow Transplantation Stem Cell Processing Center, said.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
What the Updated Telephone Consumer Protection Act Rules Mean for Health Care Messaging
April 4th 2025As new Federal Communications Commission rules take effect April 11, 2025, mPulse CEO Bob Farrell explains how health organizations can stay compliant while building patient trust through transparency and personalized engagement.
Read More
High-Impact Trials at ACC.25 Signal Shift in Chronic Disease Treatment
April 4th 2025Experts highlight groundbreaking research presented at the American College of Cardiology Annual Scientific Session (ACC.25), which emphasized a shift toward more personalized, evidence-based treatment strategies.
Read More